No changes in plasma Brain-Derived Neurotrophic Factor (BDNF) levels in Treatment-Resistant Depression patients submitted to Convulsive Therapies.

IF 3.6 3区医学 Q1 PSYCHIATRY

Revista Brasileira de Psiquiatria Pub Date : 2025-03-16 DOI:10.47626/1516-4446-2024-3983

Leonardo Afonso Dos Santos, Eric Cretaz, Helena Bellini, Adriana Munhoz Carneiro, José Gallucci-Neto, Leda Leme Tallib, André Russowsky Brunoni

{"title":"No changes in plasma Brain-Derived Neurotrophic Factor (BDNF) levels in Treatment-Resistant Depression patients submitted to Convulsive Therapies.","authors":"Leonardo Afonso Dos Santos, Eric Cretaz, Helena Bellini, Adriana Munhoz Carneiro, José Gallucci-Neto, Leda Leme Tallib, André Russowsky Brunoni","doi":"10.47626/1516-4446-2024-3983","DOIUrl":null,"url":null,"abstract":"Background: Convulsive therapies are often effective for Treatment-Resistant Depression (TRD), although their mechanisms of action are unclear. Increases in Brain-Derived Neurotrophic Factor (BDNF) levels are observed after Electroconvulsive Therapy (ECT), but more recent evidence calls this claim into question. Moreover, Magnetic Seizure Therapy (MST), a new convulsive technique, has not yet been studied regarding possible neurotrophic modulation.Methods: We performed plasma BDNF measures before and throughout treatment of adult patients (18 to 65 years old) diagnosed with TRD and submitted to treatment with convulsive therapy (ECT or MST) in the arms of the EMCODE project.Results: We enrolled 31 participants (mean age = 38.4 years, SD = 11.88), 14 (45.16%) were submitted to ECT and 17 (54.84%) to MST. Notable improvements in depressive symptoms were observed in both groups, with no significant difference between them (p = 0.1046). Meanwhile, no significant changes in BDNF plasma levels were observed for any technique, pre and post-treatment (MD = -93.01 pg/ml, 95% CI -545.88 to 359.86), or over time (Coefficient = -67.95, SE = 37.75, p = 0.072).Conclusion: The findings suggested no significant changes in plasma BDNF following convulsive therapies, challenging the notion of BDNF as a biomarker for treatment-resistant depression.","PeriodicalId":21244,"journal":{"name":"Revista Brasileira de Psiquiatria","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira de Psiquiatria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47626/1516-4446-2024-3983","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Convulsive therapies are often effective for Treatment-Resistant Depression (TRD), although their mechanisms of action are unclear. Increases in Brain-Derived Neurotrophic Factor (BDNF) levels are observed after Electroconvulsive Therapy (ECT), but more recent evidence calls this claim into question. Moreover, Magnetic Seizure Therapy (MST), a new convulsive technique, has not yet been studied regarding possible neurotrophic modulation.

Methods: We performed plasma BDNF measures before and throughout treatment of adult patients (18 to 65 years old) diagnosed with TRD and submitted to treatment with convulsive therapy (ECT or MST) in the arms of the EMCODE project.

Results: We enrolled 31 participants (mean age = 38.4 years, SD = 11.88), 14 (45.16%) were submitted to ECT and 17 (54.84%) to MST. Notable improvements in depressive symptoms were observed in both groups, with no significant difference between them (p = 0.1046). Meanwhile, no significant changes in BDNF plasma levels were observed for any technique, pre and post-treatment (MD = -93.01 pg/ml, 95% CI -545.88 to 359.86), or over time (Coefficient = -67.95, SE = 37.75, p = 0.072).

Conclusion: The findings suggested no significant changes in plasma BDNF following convulsive therapies, challenging the notion of BDNF as a biomarker for treatment-resistant depression.

查看原文本刊更多论文

接受抽搐治疗的难治性抑郁症患者血浆脑源性神经营养因子（BDNF）水平无变化。

背景：抽搐疗法通常对难治性抑郁症（TRD）有效，尽管其作用机制尚不清楚。电休克治疗（ECT）后脑源性神经营养因子（BDNF）水平升高，但最近的证据对这一说法提出了质疑。此外，磁发作疗法（MST）作为一种新的惊厥技术，尚未对其可能的神经营养调节进行研究。方法：在EMCODE项目中，我们对诊断为TRD并接受抽搐治疗（ECT或MST）的成年患者（18至65岁）在治疗前和治疗过程中进行了血浆BDNF测量。结果：31例患者（平均年龄38.4岁，SD = 11.88）， 14例（45.16%）接受ECT治疗，17例（54.84%）接受MST治疗。两组患者的抑郁症状均有显著改善，两组间差异无统计学意义（p = 0.1046）。同时，在任何一种技术中，治疗前后血浆BDNF水平均无显著变化（MD = -93.01 pg/ml, 95% CI = -545.88 ~ 359.86），或随时间变化（系数= -67.95,SE = 37.75, p = 0.072）。结论：研究结果表明抽搐治疗后血浆BDNF无显著变化，挑战了BDNF作为治疗难治性抑郁症生物标志物的概念。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Brasileira de Psiquiatria 医学-精神病学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Revista Brasileira de Psiquiatria (RBP) is the official organ of the Associação Brasileira de Psiquiatria (ABP - Brazilian Association of Psychiatry). The Brazilian Journal of Psychiatry is a bimonthly publication that aims to publish original manuscripts in all areas of psychiatry, including public health, clinical epidemiology, basic science, and mental health problems. The journal is fully open access, and there are no article processing or publication fees. Articles must be written in English.